Jiří Beran

Prof. Jiří Beran

Institute for Postgraduate Health Education in Prague
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAnn R. Falsey
Ann R. Falsey
JMJanet E. McElhaney
Janet E. McElhaney
Jiří BeranJiří Beran
Jiří Beran
GEGerrit A. van Essen
Gerrit A. van Essen
XDXavier Duval
Xavier Duval
STSylvia Taylor
Sylvia Taylor
Background. Few studies have prospectively assessed viral etiologies of acute respiratory infections in community-based elderly individuals. We assessed viral respiratory pathogens in individuals ≥65 years with influenza-like illness (ILI). Methods. Multiplex reverse-transcriptase polymerase chain reaction identified viral pathogens in nasal/throat swabs from 556 episodes of moderate-to-severe ILI, defined as ILI with pneumonia, hospitalization, or maximum daily influenza symptom severity score (ISS) >2. Cases were selected from a randomized trial of an adjuvanted vs nonadjuvanted influenza vaccine conducted in elderly adults from 15 countries. Results. Respiratory syncytial virus (RSV) was detected in 7.4% (41/556) moderate-to-severe ILI episodes in elderly adults. Most (39/41) were single infections. There was a significant association between country and RSV detection (P = .004). RSV prevalence was 7.1% (2/28) in ILI with pneumonia, 12.5% (8/64) in ILI with hospitalization, and 6.7% (32/480) in ILI with maximum ISS > 2. Any virus was detected in 320/556 (57.6%) ILI episodes: influenza A (104/556, 18.7%), rhinovirus/enterovirus (82/556, 14.7%), coronavirus and human metapneumovirus (each 32/556, 5.6%). Conclusions. This first global study providing data on RSV disease in ≥65 year-olds confirms that RSV is an important respiratory pathogen in the elderly. Preventative measures such as vaccination could decrease severe respiratory illnesses and complications in the elderly.

1 March 2002 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
TJT Jelinek
T Jelinek
CSC Schulte
C Schulte
RBR Behrens
R Behrens
MGM P Grobusch
M P Grobusch
JCJ P Coulaud
J P Coulaud
GBG Boecken
G Boecken
Malaria continues to have a high morbidity rate associated among European travelers. Thorough recording of epidemiological and clinical aspects of imported malaria has been helpful in the detection of new outbreaks and areas of developing drug resistance. Sentinel surveillance of data collected prospectively since 1999 has begun within TropNetEurop, a European network focusing on imported infectious diseases. TropNetEurop appears to cover ∼10% of all patients with malaria seen in Europe. Reports of 1659 immigrants and European patients with Plasmodium falciparum malaria were analyzed for epidemiological information and data on clinical features. Regional data were quite diverse, reflecting local patterns of immigration and international travel. By far, the most infections were imported from West Africa. Europeans had more clinical complications; consequently, all deaths occurred in this group. Compared with European standards, the mortality rate was low (0.6% in Europeans). Data from TropNetEurop member sites can contribute to our understanding of the epidemiological and clinical findings regarding imported falciparum malaria.

1 November 2005 in Kidney International
Verified
Journal Article
Closed access
NTNorella Kong Chiew Tong
Norella Kong Chiew Tong
Jiří BeranJiří Beran
Jiří Beran
SKSwee Ann Kee
Swee Ann Kee
JMJose Luis Miguel
Jose Luis Miguel
CSCarmen Sánchez
Carmen Sánchez
MSMichel Stoffel
Michel Stoffel

1 June 2013 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JMJanet E McElhaney
Janet E McElhaney
Jiří BeranJiří Beran
Jiří Beran
JDJeanne-Marie Devaster
Jeanne-Marie Devaster
MEMeral Esen
Meral Esen
OLOdile Launay
Odile Launay
LOLidia Oostvogels
Lidia Oostvogels

14 January 2008 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
Jiří BeranJiří Beran
Jiří Beran
MDMd
Md
Background: High susceptibility to infections including the hepatitis B virus (HBV) causes increased morbidity and mortality in patients with end stage renal disease. HBV vaccination is recommended for all patients undergoing dialysis; however, antibody response is much lower than in healthy individuals. Objective: This review discusses the clinical experience with HBV vaccine with a novel adjuvant system among dialysed patients. Method: A new adjuvanted HBV vaccine (Fendrix™, GlaxoSmithKline Biologicals, Rixensart, Belgium) contains as active substance 20 μg recombinant hepatitis B surface antigen produced in Saccharomyces cerevisiae and the novel adjuvant system composed of aluminum salt and 3-O-desacyl-4′-monophosphoryl lipid A (AS04). Conclusion: HBV-AS04 vaccine has a good safety profile with clinically acceptable reactions similar to standard HBV vaccines and has elicited earlier antibody response and higher antibody titres in pre and haemodialysis patients as compared with four double doses of stan...

15 April 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
NMN. Muhlberger
N. Muhlberger
TJT. Jelinek
T. Jelinek
RBR. H. Behrens
R. H. Behrens
IGI. Gjorup
I. Gjorup
JCJ. P. Coulaud
J. P. Coulaud
TNTropNetEurop and Surveillance importierter Infektionen in Deutschland (SIMPID) Surveillance Networks
TropNetEurop and Surveillance importierter Infektionen in Deutschland (SIMPID) Surveillance Networks
Previous studies have indicated that age is a risk factor for severe falciparum malaria in nonimmune patients. The objectives of this study were to r